Long‐term duration and safety of Radiesse (+) for the treatment of jawline.

Background: Calcium hydroxyapatite (CaHA)‐carboxymethylcellulose (CMC)+ has unique properties that make it optimal for lifting, contouring, and defining the jawline. This long‐term follow‐up of a randomized, multicenter, rater‐blinded trial reports efficacy and safety of CaHA‐CMC(+) through 48 and up to 60 weeks post‐treatment. Methods: Eligible patients were randomized (2:1) to the treatment or the control/delayed treatment group to receive CaHA‐CMC(+) injections in both jawlines. While touch‐ups were permitted 4 weeks post‐treatment for both groups, only the treatment group was eligible for optional retreatment after 48 weeks. The primary outcome was ≥1‐point improvement on both jawlines on the Merz Jawline Assessment Scale (MJAS); secondary endpoints included the Subject Global Aesthetic Improvement Scale (SGAIS) among others. Post hoc analysis included pooling up to 48‐week data from the combined treatment and control/delayed groups and 60‐week data for the treatment group. Results: Overall, 175 received treatment. MJAS responder rates were 77.9%, 78.7%, and 62.9% at 12, 24, and 48 weeks post‐treatment, respectively. Responder rate on the MJAS at 60 weeks was 74.6% for those who received retreatment and 43.5% for those patients who received only the initial and touchup treatments. SGAIS scores demonstrated 93.4%, 85.6%, and 68.5% of patients rated themselves very much improved after 12, 24, and 48 weeks, respectively. Adverse events consisted of procedure or CaHA‐CMC(+)‐related events that were mostly resolved and overwhelmingly mild. Conclusions: CaHA‐CMC(+) produced clinically meaningful and long‐lasting improvements in jawline contour and was well tolerated in patients through 60 weeks. Trial Registration: ClinicalTrials.gov Identifier: NCT03583359. [ABSTRACT FROM AUTHOR]